Articles

The company has pleaded guilty to violating the Federal Food, Drug and Cosmetic Act by failing to provide certain records to FDA investigators and will pay a criminal fine of $30 million, and forfeit an additional $20 million.

Fresenius Kabi Oncology Pleads Guilty to Concealing and Destroying Records Prior to FDA Inspection

MTEM will handle research activities for the discovery of the next generation of engineered toxin bodies using its ETB platform, while Bristol Myers Squibb will obtain a license to develop and commercialize the ETBs.

Bristol Myers Squibb and Molecular Templates Form $1.37-Billion R&D Collaboration

4D pharma has signed a clinical trial collaboration and supply agreement with Merck and Pfizer for Bavencio (avelumab).

4D pharma Signs Clinical Trial Collaboration and Supply Agreement with Merck and Pfizer

Rentschler Biopharma will establish its manufacturing capability for advanced therapy medicinal products at the CGT Catapult site in Stevenage, UK.

Rentschler Biopharma Establishes ATMP Manufacturing Capabilities in the UK

Optibrium, software developer for drug discovery, has raised investment from Kester Capital, a private equity firm, for the development of its business. 

Optibrium Raises Equity to Drive Development of the Business

Nanoform and Herantis have signed a biologics proof of concept agreement for formulation proof of concept projects aimed at improving nasal drug delivery to the brain.

Nanoform, Herantis Collaborate on Nasal Drug Delivery to the Brain of Biologics

Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.

Scientists and policy makers are looking more sharply at the lag in identifying and producing medicines to moderate early infections and to treat seriously ill patients. 

Where Are the Therapeutics to Combat COVID-19?

The EC has granted Vico Therapeutics with orphan drug designation for its investigational antisense oligonucleotide therapy for the treatment of SCA.



EC Grants Orphan Drug Designation to Vico Therapeutics’ Oligonucleotide SCA Therapy

Exscientia has formed a partnership with the ARUK-ODDI for the development of medicines targeting neuroinflammation to treat Alzheimer’s disease.

Exscientia Partners with University of Oxford on Alzheimer’s Treatments

The new business services site will house the company’s North American human resource operations, along with certain finance and information technology teams.

News